David Stejskal | Clinical Chemistry | Innovative Biomedical Research Award

Published on by Medical Lab Scientist

Innovative Biomedical Research Award

David Stejskal
Affiliation Institute of Laboratory Medicine, University Hospital and Faculty of Medicine, Ostrava University
Country Czech Republic
Scopus ID 7005865420
Documents 213
Citations 3,995
h-index 30
Subject Area Clinical Chemistry
Event Medical Lab Scientist Awards
ORCID 0000-0003-1204-0395

David Stejskal is a Czech researcher and laboratory medicine specialist associated with the Institute of Laboratory Medicine at University Hospital Ostrava and the Faculty of Medicine of the University of Ostrava. His scholarly activity is situated principally within clinical chemistry, laboratory diagnostics, biomarker research and related biomedical disciplines.[1]

Abstract

This academic recognition profile summarizes the documented research activity of David Stejskal in clinical chemistry, laboratory medicine and biomedical research. His publication record encompasses diagnostic biomarkers, analytical and pre-analytical laboratory problems, cardiovascular biomarker research, neurodegenerative disease biomarkers and quantitative laboratory methodology.[1]

Keywords

Clinical chemistry, laboratory medicine, biomedical research, diagnostic biomarkers, clinical biochemistry, laboratory diagnostics, microRNAs, cardiovascular biomarkers, neurodegenerative disease biomarkers, analytical chemistry, chromatography, mass spectrometry, potassium measurement, laboratory interference, translational diagnostics, University Hospital Ostrava.[2]

Introduction

Clinical chemistry provides quantitative laboratory information that supports disease detection, differential diagnosis, monitoring and clinical decision-making. Contemporary laboratory medicine increasingly combines conventional biochemical testing with molecular biomarkers, advanced analytical technologies and rigorous assessment of factors that can influence laboratory results.[2]

Research Profile

David Stejskal is affiliated with the Institute of Laboratory Medicine in Ostrava, Czech Republic, with published research identifying connections to University Hospital Ostrava and the Faculty of Medicine at the University of Ostrava. His ORCID identifier, 0000-0003-1204-0395, provides a persistent scholarly identifier for author attribution and research discovery.[3]

Research Contributions

One component of Stejskal’s work concerns clinically important laboratory measurement and interpretation. A 2024 report on pseudonormokalemia examined circumstances in which serum potassium can appear to remain within a reference interval despite a substantially different plasma potassium concentration, particularly in the setting of thrombocytosis.[3]

Publications

David Stejskal’s research portfolio demonstrates broad contributions to laboratory medicine, clinical biochemistry, molecular biomarkers, and diagnostic research. His publications address important topics including pseudonormokalemia and potassium measurement, circulating microRNAs in heart failure, advanced mass-spectrometric quantification of insulin and insulin analogues, urinary fetuin-A in urolithiasis, and urinary N1,N12-diacetylspermine as a potential bladder-cancer marker.[4]

Research Impact

The supplied Scopus indicators report 213 indexed documents, 3,995 citations and an h-index of 30 for David Stejskal. In bibliometric terms, document count reflects indexed scholarly output, total citations indicate how frequently indexed publications have been cited by subsequent literature, and the h-index combines aspects of publication productivity and citation distribution.[4]

Award Suitability

For consideration under the Innovative Biomedical Research Award within the Medical Lab Scientist Awards, Stejskal’s documented profile presents several characteristics relevant to an academic evaluation. These include a substantial indexed publication record, sustained citation activity, research within clinical chemistry and laboratory medicine, participation in biomarker-oriented investigations and contributions to analytical and diagnostic methodology.[5]

Conclusion

David Stejskal’s academic profile reflects sustained activity in clinical chemistry, laboratory medicine and biomedical research. His documented work encompasses clinically relevant laboratory interpretation, molecular and biochemical biomarkers, neurodegenerative and cardiovascular research and advanced analytical methodology.[5]

References

  1. Elsevier. (n.d.). Scopus author details: David Stejskal, Author ID 7005865420. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7005865420
  2. ORCID. (n.d.). ORCID record: David Stejskal, 0000-0003-1204-0395. ORCID.
    https://orcid.org/0000-0003-1204-0395
  3. Medical Lab Scientist Awards. (n.d.). Medical Lab Scientist Awards academic and scientific recognition platform.
    https://medicallabscientist.com/
  4. Chobolová, N., Švagera, Z., Stejskal, D., & Bužga, M. (2026). Candidate circulating microRNAs in patients with sarcopenic obesity: Results of a pilot screening. Biomedicines, 14(6), 1377.
    https://doi.org/10.3390/biomedicines14061377
  5. Zhang, X., Yeung, D. C. Y., Karpisek, M., Stejskal, D., Zhou, Z.-G., Liu, F., Wong, R. L. C., Chow, W.-S., Tso, A. W. K., Lam, K. S. L., & Xu, A. (2008). Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes, 57(5), 1246–1253.
    https://doi.org/10.2337/db07-1476